JPS5657712A - Carcinostatic agent - Google Patents

Carcinostatic agent

Info

Publication number
JPS5657712A
JPS5657712A JP13339279A JP13339279A JPS5657712A JP S5657712 A JPS5657712 A JP S5657712A JP 13339279 A JP13339279 A JP 13339279A JP 13339279 A JP13339279 A JP 13339279A JP S5657712 A JPS5657712 A JP S5657712A
Authority
JP
Japan
Prior art keywords
cancerous cell
dihydroxybenzaldoxime
pax
day
agent containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP13339279A
Other languages
Japanese (ja)
Inventor
Makoto Umeda
Akio Kusanagi
Masaru Nishimura
Shigeki Otawara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyobo Co Ltd
Original Assignee
Toyobo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyobo Co Ltd filed Critical Toyobo Co Ltd
Priority to JP13339279A priority Critical patent/JPS5657712A/en
Publication of JPS5657712A publication Critical patent/JPS5657712A/en
Pending legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PURPOSE: To provide a benzaldehyde-type carcinostatic agent containing 3,4-dihydroxybenzaldoxime as an effective component.
CONSTITUTION: An agent containing 3,4-dihydroxybenzaldoxime (procatechualdehyde: abbr. PAX) as an effective component. Similar to 3,4-dihydroxybenzaldehyde which has been found by the inventors, the compound causes the selective dissapearance of the fission image of human cancerous cell, and the enlargement of the cancerous cell and nucleus compared with normal human cell. The phenomena prove the selective DNA synthesis inhibiting action of the compound to the cancerous cell. The effective dose of PAX is pref. 0.1W30mg/kg/day for oral administration and 0.1W20mg/kg/day for parenteral administration.
COPYRIGHT: (C)1981,JPO&Japio
JP13339279A 1979-10-15 1979-10-15 Carcinostatic agent Pending JPS5657712A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP13339279A JPS5657712A (en) 1979-10-15 1979-10-15 Carcinostatic agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP13339279A JPS5657712A (en) 1979-10-15 1979-10-15 Carcinostatic agent

Publications (1)

Publication Number Publication Date
JPS5657712A true JPS5657712A (en) 1981-05-20

Family

ID=15103665

Family Applications (1)

Application Number Title Priority Date Filing Date
JP13339279A Pending JPS5657712A (en) 1979-10-15 1979-10-15 Carcinostatic agent

Country Status (1)

Country Link
JP (1) JPS5657712A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001043712A1 (en) * 1999-12-14 2001-06-21 Haarmann & Reimer Gmbh Catechol oximes and their use in cosmetic and dermatological preparations
US6693126B2 (en) * 2000-10-27 2004-02-17 Choongwae Pharm. Co., Ltd. Dihydroxyphenyl derivatives for hepatoprotection and treatment of liver diseases
KR100919624B1 (en) * 2007-09-11 2009-09-30 경북대학교 산학협력단 Composition for prevention and treatment for leukemia comprising 3,4-dihydroxybenzaldehyde extracted from Xanthium strumarium
CN110693862A (en) * 2019-11-02 2020-01-17 上海中医药大学附属岳阳中西医结合医院 Application of protocatechualdehyde in inhibiting CtBP1

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001043712A1 (en) * 1999-12-14 2001-06-21 Haarmann & Reimer Gmbh Catechol oximes and their use in cosmetic and dermatological preparations
US6693126B2 (en) * 2000-10-27 2004-02-17 Choongwae Pharm. Co., Ltd. Dihydroxyphenyl derivatives for hepatoprotection and treatment of liver diseases
KR100919624B1 (en) * 2007-09-11 2009-09-30 경북대학교 산학협력단 Composition for prevention and treatment for leukemia comprising 3,4-dihydroxybenzaldehyde extracted from Xanthium strumarium
CN110693862A (en) * 2019-11-02 2020-01-17 上海中医药大学附属岳阳中西医结合医院 Application of protocatechualdehyde in inhibiting CtBP1

Similar Documents

Publication Publication Date Title
JPS52128210A (en) Preparation of soft capsule for 1alpha-hydroxyvitamind derivatives
JPS5657712A (en) Carcinostatic agent
JPS5470428A (en) Carcinostatic agent
JPS5352622A (en) Composition for preparation of bordeaux mixture
JPS5217499A (en) Preparation of mappicine
JPS5233624A (en) Preparation of leucylnitroagmatines
JPS5273878A (en) Synthesis of 6-carboxyacetyl-3,4-dihydrocarbostyril
JPS5498791A (en) Anti-asthmatic drug
JPS525769A (en) Preparation of 3-substituted pyrolidine derivatives
JPS51136886A (en) New biologica lly active substance, ml-236c, and its preparation
JPS5430185A (en) Mandelic acid derivative and carcinostatic agnet containing the same
JPS5283421A (en) Preparation of phenoxypropylamine derivatives
JPS5283413A (en) Preparation of 3,3-dimethyl-4-pentenoic acid or its esters
JPS5323906A (en) 6-methyl-3-methylene-1,6-octadiene and its preparation
JPS5346937A (en) Preparation of n-p-aminobenzoyl-n,-p-aminourea
JPS525782A (en) Preparation of 1-phthalazinone
JPS5251032A (en) Medicines of disaccharide-glutathione derivatives
JPS52118453A (en) Indene derivatives
JPS52144631A (en) Inclusion composition, its preparation and separation of #-diethylbenzene from #-diethylbenzene-containing mixture
JPS53147050A (en) 1,4-naphthoquinone-2,3-oxotriphenyl-phosphorane and process for their preparation
JPS55130914A (en) Novel antiallergic agent
JPS5248692A (en) Preparation of homo-pyriimidazole derivatives
JPS5341414A (en) Hydrate crystals of carbocromene hydrochloride
JPS57159711A (en) Low oxygen cell sensitizer for radiation
JPS525794A (en) Preparation of 4-hydroxy-or 4,6-dihydroxy- 1h-pyrazolo-(3,4-d)pyrimidi ne